Cargando…

Immunotherapy for the treatment of hepatocellular carcinoma: finally in clinical practice

Detalles Bibliográficos
Autores principales:	Celsa, Ciro, Cerrito, Lucia, Stella, Leonardo, Ciccia, Roberta, Cabibbo, Giuseppe, Ponziani, Francesca Romana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Editorial Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10129882/ https://www.ncbi.nlm.nih.gov/pubmed/37124696 http://dx.doi.org/10.21037/hbsn-23-97

Ejemplares similares

The Society for Immunotherapy of Cancer clinical practice guideline on immunotherapy for hepatocellular carcinoma
por: Kudo, Masatoshi
Publicado: (2023)

The New Era of Systemic Treatment for Hepatocellular Carcinoma: From the First Line to the Optimal Sequence
por: Cerreto, Maria, et al.
Publicado: (2023)

Mechanisms of Resistance to Immunotherapy in Hepatocellular Carcinoma
por: Manfredi, Giulia Francesca, et al.
Publicado: (2023)

Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma
por: Cabibbo, Giuseppe, et al.
Publicado: (2020)

Viral hepatitis and hepatocellular carcinoma: From molecular pathways to the role of clinical surveillance and antiviral treatment
por: Stella, Leonardo, et al.
Publicado: (2022)

Treatment of hepatocellular carcinoma in patients with portal vein tumor thrombosis: Beyond the known frontiers
por: Cerrito, Lucia, et al.
Publicado: (2019)

Immunotherapy for nonalcoholic fatty liver disease-related hepatocellular carcinoma: Lights and shadows
por: Costante, Federico, et al.
Publicado: (2022)

Prognostic scores for hepatocellular carcinoma: none is the winner
por: Cammà, Calogero, et al.
Publicado: (2009)

Combined locoregional and systemic therapy for advanced hepatocellular carcinoma: finally, the future is obscure
por: Farsad, Khashayar, et al.
Publicado: (2020)

The Evolving Scenario in the Assessment of Radiological Response for Hepatocellular Carcinoma in the Era of Immunotherapy: Strengths and Weaknesses of Surrogate Endpoints
por: Giuffrida, Paolo, et al.
Publicado: (2022)

Molecular and Clinical Features of Hepatocellular Carcinoma in Patients with HBV-HDV Infection
por: Costante, Federico, et al.
Publicado: (2023)

Lipids link immune suppression to effective immunotherapy in steatotic hepatocellular carcinoma
por: Li, Bing, et al.
Publicado: (2023)

Non-Invasive Biomarkers for Immunotherapy in Patients with Hepatocellular Carcinoma: Current Knowledge and Future Perspectives
por: Pallozzi, Maria, et al.
Publicado: (2022)

Microvascular Thrombosis and Liver Fibrosis Progression: Mechanisms and Clinical Applications
por: Airola, Carlo, et al.
Publicado: (2023)

Optimizing Sequential Systemic Therapies for Advanced Hepatocellular Carcinoma: A Decision Analysis
por: Cabibbo, Giuseppe, et al.
Publicado: (2020)

Role of LI-RADS Indeterminate Observations in the Risk of Hepatocellular Carcinoma after HCV Eradication with Direct-Acting Antivirals
por: Vernuccio, Federica, et al.
Publicado: (2022)

Diagnostic and therapeutic potential of the gut microbiota in patients with early hepatocellular carcinoma
por: Ponziani, Francesca Romana, et al.
Publicado: (2019)

Combining immunotherapy and radiotherapy in hepatocellular carcinoma: the importance of irradiated tumor burden and the possible role of a low dose radiotherapy induction strategy
por: Grassberger, Clemens, et al.
Publicado: (2023)

Editorial of Special Issues “Gut Microbiota–Host Interactions: From Symbiosis to Dysbiosis 2.0”
por: Zuccaro, Valentina, et al.
Publicado: (2023)

Challenges and Future Trends of Hepatocellular Carcinoma Immunotherapy
por: Rizzo, Alessandro, et al.
Publicado: (2022)

A new era for hepatocellular carcinoma
por: Memeo, Riccardo, et al.
Publicado: (2023)

Obesity and non-alcoholic steatohepatitis in immunotherapy for hepatocellular carcinoma
por: Shiina, Shuichiro, et al.
Publicado: (2023)

The tango of immunotherapy and targeted therapy in metastatic renal cell carcinoma
por: Rathi, Nityam, et al.
Publicado: (2019)

Doxorubicin for the treatment of hepatocellular carcinoma: GAME OVER!
por: Guiu, Boris, et al.
Publicado: (2020)

Immunotherapy in cervical cancer: the advent of precision medicine
por: De Felice, Francesca, et al.
Publicado: (2020)

The Burden of Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: Screening Issue and Future Perspectives
por: Pennisi, Grazia, et al.
Publicado: (2019)

Tivozanib for hepatocellular carcinoma: not likely a new option
por: Estrade, Florian, et al.
Publicado: (2020)

Racism: the shameful practices that the medical profession is finally addressing
por: Burnett-Bowie, Sherri-Ann M., et al.
Publicado: (2021)

Immunotherapy for penile cancer
por: Buonerba, Carlo, et al.
Publicado: (2017)

Angiogenesis inhibitors for advanced hepatocellular carcinoma: in search for the right partner
por: Campani, Claudia, et al.
Publicado: (2020)

Adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma
por: Kudo, Masatoshi
Publicado: (2023)

In silico trials of combination immuno-radiation for unresectable hepatocellular carcinoma
por: Mendiratta-Lala, Mishal, et al.
Publicado: (2023)

Update on new approaches in the management of hepatocellular carcinoma
por: Cabibbo, Giuseppe, et al.
Publicado: (2010)

T and NK Cell-Based Immunotherapy in Chronic Viral Hepatitis and Hepatocellular Carcinoma
por: Fisicaro, Paola, et al.
Publicado: (2022)

Evolving treatment paradigms in recurrent and metastatic head and neck squamous cell carcinoma: the emergence of immunotherapy
por: Faraji, Farhoud, et al.
Publicado: (2023)

The role of c-MET inhibitors in advanced hepatocellular carcinoma: now and future
por: Woo, Hyun Young, et al.
Publicado: (2020)

Tivozanib in advanced inoperable hepatocellular carcinoma: considerations for patients with liver cirrhosis
por: Oh, Hyunwoo, et al.
Publicado: (2020)

Sorafenib plus doxorubicin in advanced hepatocellular carcinoma patients: hope or hype?
por: Shing, Kit, et al.
Publicado: (2020)

May an aspirin a day truly take hepatocellular carcinoma away?
por: Giannini, Edoardo G., et al.
Publicado: (2023)

Atezolizumab plus bevacizumab and tremelimumab plus durvalumab: how should we choose these two immunotherapy regimens for advanced hepatocellular carcinoma?
por: Hatanaka, Takeshi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tn705i7e37242di9a6v2vum9sk